Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 70
Page 7
... Tumor (T). Adenocarcinoma represents about 40% of lung cancer cases in the United States. It is the most common form ... tumors are correlated with increased survival in early stage disease, whereas squamoid tumors are associated with ...
... Tumor (T). Adenocarcinoma represents about 40% of lung cancer cases in the United States. It is the most common form ... tumors are correlated with increased survival in early stage disease, whereas squamoid tumors are associated with ...
Page 8
... tumors within the lobe of the lung with the primary tumor is classified as T4, and an in- trapulmonary ipsilateral distant metastasis is classified as M1. Even though the tumor-nodes-metastasis (TNM) staging classification in Table 1–6 ...
... tumors within the lobe of the lung with the primary tumor is classified as T4, and an in- trapulmonary ipsilateral distant metastasis is classified as M1. Even though the tumor-nodes-metastasis (TNM) staging classification in Table 1–6 ...
Page 9
... tumor cannot be assessed, or tumor is proven by the presence of malignant cells in sputum or bronchial washings but cannot be visualized by imaging or bronchoscopy. T0 No evidence of primary tumor. Tis Carcinoma in situ. T1 Tumor 3 cm ...
... tumor cannot be assessed, or tumor is proven by the presence of malignant cells in sputum or bronchial washings but cannot be visualized by imaging or bronchoscopy. T0 No evidence of primary tumor. Tis Carcinoma in situ. T1 Tumor 3 cm ...
Page 10
... tumor (T), regional lymph node (N), and distant metastasis (M). Source: Used with the permission of the American Joint Committee on Cancer (AJCC®), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging ...
... tumor (T), regional lymph node (N), and distant metastasis (M). Source: Used with the permission of the American Joint Committee on Cancer (AJCC®), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging ...
Page 11
... tumor • Tis: Carcinoma in situ • T1: Tumor that is 3 cm in its greatest dimension, does not invade the visceral pleura, and is without bronchoscopic evidence of invasion more proximal than a lobar bronchus T1a: Tumor is 2 cm in its ...
... tumor • Tis: Carcinoma in situ • T1: Tumor that is 3 cm in its greatest dimension, does not invade the visceral pleura, and is without bronchoscopic evidence of invasion more proximal than a lobar bronchus T1a: Tumor is 2 cm in its ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss